- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06216132
A Phase 1, Placebo-controlled, Single-Ascending-Dose, Study of BIOPIN 6 in Healthy Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Naltrexone (NTX) is a medication that helps people with opioid and alcohol dependence. It works by blocking the effects of opioids like heroin in the body. In the United States, participants can get NTX in two forms: a pill participants take once a day (Revia) and a shot participants get once a month (Vivitrol). Even though NTX is good at stopping the effects of opioids, some people find it hard to take it regularly. That's why scientists are looking into making a new version of NTX that participants only need to take once a month. This could make it easier for people with opioid use problems to stick with their treatment plan.
The device being tried out in this research is called BIOPIN-6. It's made to stay in the body for more than a month. The study will go on for three months and aims to check if the BIOPIN-6 is safe and how much medicine it releases into the blood. Once the three months are up, the device will be taken out.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Eva Kemper, MSHS
- Phone Number: 7278979000
- Email: ekemper@cogres.com
Study Contact Backup
- Name: Steven Cohen, MD
- Phone Number: 7274603015
- Email: scohen@rvaf.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to be included in the study:
- Healthy male or female volunteer, aged 18-to-55 years, inclusive.
- BMI must be between 18 and 32 kg/m2 (inclusive) and weigh a minimum of 50 kg (110 lbs).
If female, be postmenopausal (at least 2 years prior to dosing) or agree to use an acceptable form of birth control from screening until 12 weeks after dosing. Subjects who claim postmenopausal status will have status confirmed with a follicle stimulating hormone (FSH) test. Acceptable forms of birth control for females include the following:
- Vasectomized partner (at least 6 months prior to dosing)
- Surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) at least 6 months prior to dosing
- Non-surgical permanent sterilization (eg, Essure procedure) at least 3 months prior to dosing.
- Abstinence (must agree to use a double barrier method if they become sexually active during the study)
- Double barrier (diaphragm with spermicide; condoms with spermicide)
- Oral hormonal contraceptives
- Not Breast feeding
- Negative tests for human immunodeficiency virus (HIV), Hepatitis C antibody, Hepatitis B surface antigen, and Covid
- Able and willing to comply with the requirements of the protocol
- Able and willing to provide written informed consent
- Willing to undergo a minor surgical procedure under local anesthetic to allow for investigational drug administration in the subcutaneous tissue
- Agree to avoid blunt trauma to the implantation site
- Agree that after implantation, not to shower for 2 days and not to bathe/swim for 4 weeks
Exclusion Criteria:
Subjects must have none of the exclusion criteria to be included in the study.
- Clinically significant abnormal finding on the physical exam, medical history, electrocardiogram (EKG), or clinical laboratory results at screening. In particular, values of liver function tests (ALT, AST, bilirubin, albumin, GGT) and kidney function tests (creatinine, blood urea nitrogen) and reticulocytes shall not deviate by more than 25% from the ranges of normal.
- Blood pressure: systolic >140 mmHg, diastolic >90 mmHg. [Europe Soc Hypertension guidelines]
- Heart rate: >100 beats/minute.
- Hemoglobin for female <11.5 and for male <12.5 are excluded.
- Have a known or suspected history or family history of adverse reactions or hypersensitivity to the study drugs or to drugs with a similar chemical structure.
- History or presence of gastrointestinal, hepatic or renal disease, or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
- Is on anticoagulant medications other than aspirin or NSAIDs. Agree to stop aspirin or NSAIDs 1 week prior to Biopin 6 implantation
- Used any over-the-counter (OTC) medication, nutritional or dietary supplements, herbal preparations, or vitamins within 7 days prior to the first dose of medication.
- Used any prescription medication within 14 days prior to the first dose of study medication.
More than moderate drinking averaged over the last month as assessed by history:
o Moderate drinking is here defined as up to 3 drinks per week. The standard drink will be defined by the guidelines of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and will contain no more than 14 g of alcohol.
- Smoking: Use of tobacco or nicotine-containing products within the 3-month period preceding study drug administration is exclusionary.
- Positive urine drug screen for amphetamines, barbiturates, benzodiazepines, cocaine, opiates, cannabinoids, phencyclidine, propoxyphene, methadone, methaqualone, and alcohol at the screening and Day -1 tests.
- Any methadone use 14 days prior to screening, and up to Study Day -1.
- Has had a naltrexone implant in the past 24 months.
- Has received treatment with an extended naltrexone product (e.g. Vivitrol) in the past 12 months.
- Fails the naloxone challenge test
- Has a condition which requires treatment with opioid based medication.
- Has a known hypersensitivity to naltrexone.
- Has a known hypersensitivity to materials based on poly-d-l Lactic Acid and polycaprolactone (e.g. biodegradable sutures, surgical implants or previous biodegradable implants).
- Has a known hypersensitivity to local anesthesia.
- Is prone to skin rashes, irritation or has a skin condition such as recurrent eczema that is likely to impact the implant site area, or as determined by the evaluating physician.
- Is known to form keloids at the site of skin injury.
- Demonstrates any abnormal skin tissue in the proposed implantation area
- Previous surgery to the upper abdominal wall
- Donated blood or plasma within 30 days prior to the first dose of study medication.
- Participated in another clinical trial within 30 days prior to the first dose of study medication.
- Is participating or intending to participate in any other clinical trial during the duration of this study.
- Any elevated risk for suicide measured using the Columbia Suicide Severity Rating Scale, endorsing any of the items in the past month (C-SSRS, Lifetime)
- Not as much as "mild" depression as measured by the HAM-D17 test: HAM-D17 score must be 0-10.
- Any additional condition(s) that in the investigator's opinion would prohibit the participant from completing the study or would not be in the best interest of the participant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIOPIN-6 active implant
3 sequential cohorts receiving 4.8, 9.6, or 14.4 g BIOPIN 6 implanted into a subcutaneous pocket in the upper abdominal wall.
|
An extended release formulation of naltrexone implanted in the subcutaneous space.
Other Names:
|
Placebo Comparator: BIOPIN-6 placebo implant
The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.
|
The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Naltrexone plasma levels (average)
Time Frame: Day 0 to Day 98
|
Naltrexone Area under the plasma concentration versus time curve (AUC) [(ng/ml) x hr]
|
Day 0 to Day 98
|
Naltrexone plasma levels (peak)
Time Frame: Day 0 to Day 98
|
Naltrexone Peak Plasma Concentration (Cmax) [ng/ml]
|
Day 0 to Day 98
|
Naltrexone plasma levels (peak onset)
Time Frame: Day 0 to Day 98
|
Naltrexone time to peak plasma concentration (Tmax) [hr]
|
Day 0 to Day 98
|
6-b-natlrexol plasma levels
Time Frame: Day 0 to Day 98
|
6-b-naltrexol Area under the plasma concentration versus time curve (AUC) [(ng/ml) x hr]
|
Day 0 to Day 98
|
6-b-natlrexol plasma levels (peak)
Time Frame: Day 0 to Day 98
|
6-b-naltrexol Peak Plasma Concentration (Cmax) [ng/ml]
|
Day 0 to Day 98
|
6-b-natlrexol plasma levels (time to onset of peak))
Time Frame: Day 0 to Day 98
|
6-b-naltrexol time to peak plasma concentration (Tmax) [hr]
|
Day 0 to Day 98
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Day 0 to Day 98
|
Number of participants with adverse events as assessed by CTCAE v5.
|
Day 0 to Day 98
|
Clinical laboratory values
Time Frame: Day 0 to Day 98
|
Number of participants with laboratory abnormalities as assessed by CTCAE v5.
|
Day 0 to Day 98
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Todd Bertoch, MD, CenExel JBR
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIOPIN101
- 5UG3DA048338-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-use Disorder | Cocaine Use Disorder | Healthy Controls | Marijuana Use DisorderUnited States
Clinical Trials on BIOPIN-6 Active Implant with Naltrexone
-
Cedars-Sinai Medical CenterNational Institutes of Health (NIH); Indiana UniversityRecruitingAtrial FibrillationUnited States
-
Kafrelsheikh UniversityRecruitingDental Implant Failed | Alveolar Bone LossEgypt
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Research Foundation for Mental Hygiene...Completed
-
Dentsply Sirona Implants and ConsumablesCompletedJaw, Edentulous, PartiallyUnited States, Austria, Poland, Spain, Switzerland
-
SetPoint Medical CorporationActive, not recruitingRheumatoid ArthritisUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)TerminatedBrain and Central Nervous System TumorsUnited States
-
Fundacio d'Investigacio en Atencio Primaria Jordi...CompletedPain | Virtual Reality | Pediatrics | VaccinationSpain
-
University of SydneyDana-Farber Cancer Institute; University of Southern California; Cambridge University... and other collaboratorsRecruitingGerm Cell TumorAustralia, New Zealand, United States
-
National Cancer Institute (NCI)CompletedT-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States